Cardio Diagnostics Holdings, Inc. (CDIO) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Cardio Diagnostics Holdings, Inc. is a medical technology company developing AI-driven DNA biomarker testing for cardiovascular disease. The company operates as a single segment focused on product testing, primarily offering the Epi+Gen CHD and PrecisionCHD tests. The financial statements have been retroactively restated to reflect a 1-for-30 reverse stock split that became effective on May 12, 2025, to regain compliance with Nasdaq listing requirements.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $940 | $15,928 |
| Net Loss | $(1,635,064) | $(4,163,584) |
| Loss Per Share (Basic & Diluted) | $(0.97) | $(5.93) |
| Cash and Cash Equivalents (End of Period) | $9,688,719 | $1,563,139 |
| Total Assets | $12,282,118 | $10,615,312 |
| Total Liabilities | $904,998 | $1,057,524 |
| Net Cash Used in Operating Activities | $(1,400,101) | $(1,233,050) |
| Net Cash Provided by Financing Activities | $3,308,748 | $1,582,607 |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased to $940 from $15,928 in Q1 2024, reflecting minimal commercial sales volume.
- Significant Reduction in Net Loss: Net loss improved by approximately $2.5 million year-over-year. This was primarily driven by a drastic reduction in stock-based compensation expenses within General and Administrative (G&A) costs, which fell from $2.52 million in Q1 2024 to $30,612 in Q1 2025.
- Capital Raising: The company raised approximately $3.42 million in net proceeds from the sale of common stock via an At-the-Market (ATM) issuance program during Q1 2025, compared to $1.72 million in Q1 2024.
- Amortization Increase: Amortization expense increased to $45,438 from $4,793, largely due to patent cost amortization.
Outlook, Risks, and Management Commentary
- Liquidity and Capital Needs: Management states that existing cash ($9.7 million) and ongoing ATM offerings are expected to fund operations for the next 12 months. However, the company expects to continue incurring losses and will need to raise additional capital to fund long-term growth, laboratory setup, and FDA submission activities.
- Regulatory Developments: A federal district court vacated the FDA's final rule regarding Laboratory Developed Tests (LDTs) on March 31, 2025, ruling that LDTs do not meet the definition of a medical device. This removes the immediate requirement for premarket authorization that was set to phase in on May 6, 2025.
- Reverse Stock Split: The 1-for-30 reverse stock split was executed to cure non-compliance with Nasdaq's minimum bid price requirement. The stock began trading on a post-split basis on May 13, 2025.
- Internal Controls: Management identified a material weakness in internal controls over financial reporting due to inadequate segregation of duties caused by limited staff. Remediation plans, including approval matrices and automation, are in progress but not yet fully implemented.
- Legal Contingencies: The company faces potential claims regarding success fees from terminated placement agent agreements (Boustead Securities, Benchmark Company, Northland Securities). Management disputes these claims and believes they will not have a material adverse impact, though no legal proceedings have been instigated.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $9.7 million cash balance against the burn rate of ~$1.4 million per quarter to confirm the 12-month liquidity assertion.
- Revenue Trajectory: Assess the sustainability of revenue generation given the decline to $940 in Q1 2025 and the long sales cycles mentioned in management commentary.
- Stock-Based Compensation Volatility: Note that the significant improvement in net loss was driven by the absence of a large stock compensation charge in Q1 2025 compared to Q1 2024; future quarters may vary based on equity grants.
- Internal Control Remediation: Monitor the progress of remediation for the material weakness in internal controls to ensure future financial reporting reliability.
- Legal Claims Status: Track the status of the disputed fee claims from Boustead, Benchmark, and Northland to ensure no unexpected liabilities materialize.